News coverage about Vital Therapies (NASDAQ:VTL) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vital Therapies earned a news sentiment score of 0.25 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.3535818104058 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Options Traders Expect Huge Moves in Vital Therapies (VTL) Stock (zacks.com)
- Vital Therapies (VTL) Lowered to Sell at Zacks Investment Research (americanbankingnews.com)
- Edited Transcript of VTL earnings conference call or presentation 13-Mar-18 8:30pm GMT (finance.yahoo.com)
- Vital Therapies Inc to Post Q1 2018 Earnings of ($0.36) Per Share, William Blair Forecasts (VTL) (americanbankingnews.com)
VTL stock remained flat at $$5.95 during midday trading on Wednesday. 151,751 shares of the stock were exchanged, compared to its average volume of 169,888. The company has a market capitalization of $252.10, a price-to-earnings ratio of -4.47 and a beta of 4.63. Vital Therapies has a 52-week low of $2.25 and a 52-week high of $6.70.
VTL has been the topic of several analyst reports. Raymond James Financial reiterated a “buy” rating on shares of Vital Therapies in a report on Tuesday, December 5th. BidaskClub upgraded shares of Vital Therapies from a “sell” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, Zacks Investment Research lowered shares of Vital Therapies from a “hold” rating to a “sell” rating in a report on Saturday.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Vital Therapies (NASDAQ:VTL) Share Price” was first reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://baseballnewssource.com/2018/03/22/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-vital-therapies-vtl-stock-price/1925007.html.
About Vital Therapies
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.